• PGxDB
    • About PGxDB
    • Give feedback
    • Contribute to PGxDB/ Scientific collaboration
  • Drugs
    • Drug search
    • Drug statistics
  •   Targets
    • Target search
    • Target statistics
  • Variants
    • Variant search
    • Chromosome/contig name mappings
  • Indication
    • Indication search
    • Indication statistics
  • ATC codes
    • ATC classification hierachy browser
    • ATC code statistics
  •   Tutorial
    • Tutorial
    • Use case examples
  • APIs
    • List of API endpoints
    • API sample scripts
  • Info
    • INFORMATION
    • Documentation
    • ABOUT US
    • Contact
    • Legal notice
    • Citing PGxDB
<< Return to ATC tree rooot
  • L - Antineoplastic and immunomodulating agents
    • L01 - Antineoplastic agents
      • L01A - Alkylating agents
        • L01AA - Nitrogen mustard analogues
          • L01AA01 -

            Cyclophosphamide

          • L01AA02 -

            Chlorambucil

          • L01AA03 -

            Melphalan

          • L01AA05 -

            Chlormethine

          • L01AA06 -

            Ifosfamide

          • L01AA07 -

            Trofosfamide

          • L01AA08 -

            Prednimustine

          • L01AA09 -

            Bendamustine

          • L01AA10 -

            Melphalan flufenamide

        • L01AB - Alkyl sulphonates
          • L01AB01 -

            Busulfan

          • L01AB02 -

            Treosulfan

          • L01AB03 -

            Mannosulfan

        • L01AC - Ethylene imines
          • L01AC01 -

            Thiotepa

          • L01AC02 -

            Triaziquone

          • L01AC03 -

            Carboquone

        • L01AD - Nitrosoureas
          • L01AD01 -

            Carmustine

          • L01AD02 -

            Lomustine

          • L01AD03 -

            Semustine

          • L01AD04 -

            Streptozocin

          • L01AD05 -

            Fotemustine

          • L01AD06 -

            Nimustine

          • L01AD07 -

            Ranimustine

          • L01AD08 -

            Uramustine

        • L01AG - Epoxides
          • L01AG01 -

            Etoglucid

        • L01AX - Other alkylating agents
          • L01AX01 -

            Mitobronitol

          • L01AX02 -

            Pipobroman

          • L01AX03 -

            Temozolomide

          • L01AX04 -

            Dacarbazine

      • L01B - Antimetabolites
        • L01BA - Folic acid analogues
          • L01BA01 -

            Methotrexate

          • L01BA03 -

            Raltitrexed

          • L01BA04 -

            Pemetrexed

          • L01BA05 -

            Pralatrexate

        • L01BB - Purine analogues
          • L01BB02 -

            Mercaptopurine

          • L01BB03 -

            Tioguanine

          • L01BB04 -

            Cladribine

          • L01BB05 -

            Fludarabine

          • L01BB06 -

            Clofarabine

          • L01BB07 -

            Nelarabine

        • L01BC - Pyrimidine analogues
          • L01BC01 -

            Cytarabine

          • L01BC02 -

            Fluorouracil

          • L01BC03 -

            Tegafur

          • L01BC04 -

            Carmofur

          • L01BC05 -

            Gemcitabine

          • L01BC06 -

            Capecitabine

          • L01BC07 -

            Azacitidine

          • L01BC08 -

            Decitabine

          • L01BC09 -

            Floxuridine

          • L01BC52 -

            Fluorouracil, combinations

          • L01BC53 -

            Tegafur, comb.

          • L01BC59 -

            Trifluridine, combinations

      • L01C - Plant alkaloids and other natural products
        • L01CA - Vinca alkaloids and analogues
          • L01CA01 -

            Vinblastine

          • L01CA02 -

            Vincristine

          • L01CA03 -

            Vindesine

          • L01CA04 -

            Vinorelbine

          • L01CA05 -

            Vinflunine

          • L01CA06 -

            Vintafolide

        • L01CB - Podophyllotoxin derivatives
          • L01CB01 -

            Etoposide

          • L01CB02 -

            Teniposide

        • L01CC - Colchicine derivatives
          • L01CC01 -

            Demecolcine

        • L01CD - Taxanes
          • L01CD01 -

            Paclitaxel

          • L01CD02 -

            Docetaxel

          • L01CD03 -

            Paclitaxel poliglumex

          • L01CD04 -

            Cabazitaxel

        • L01CE - Topoisomerase 1 (TOP1) inhibitors
          • L01CE01 -

            Topotecan

          • L01CE02 -

            Irinotecan

          • L01CE03 -

            Etirinotecan pegol

          • L01CE04 -

            Belotecan

        • L01CX - Other plant alkaloids and natural products
          • L01CX01 -

            Trabectedin

      • L01D - Cytotoxic antibiotics and related substances
        • L01DA - Actinomycin
          • L01DA01 -

            Dactinomycin

        • L01DB - Anthracyclines and related substances
          • L01DB01 -

            Doxorubicin

          • L01DB02 -

            Daunorubicin

          • L01DB03 -

            Epirubicin

          • L01DB04 -

            Aclarubicin

          • L01DB05 -

            Zorubicin

          • L01DB06 -

            Idarubicin

          • L01DB07 -

            Mitoxantrone

          • L01DB08 -

            Pirarubicin

          • L01DB09 -

            Valrubicin

          • L01DB10 -

            Amrubicin

          • L01DB11 -

            Pixantrone

        • L01DC - Other cytotoxic antibiotics
          • L01DC01 -

            Bleomycin

          • L01DC02 -

            Plicamycin

          • L01DC03 -

            Mitomycin

          • L01DC04 -

            Ixabepilone

      • L01E - Protein kinase inhibitors
        • L01EA - BCR-ABL tyrosine kinase inhibitors
          • L01EA01 -

            Imatinib

          • L01EA02 -

            Dasatinib

          • L01EA03 -

            Nilotinib

          • L01EA04 -

            Bosutinib

          • L01EA05 -

            Ponatinib

          • L01EA06 -

            Asciminib

        • L01EB - Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors
          • L01EB01 -

            Gefitinib

          • L01EB02 -

            Erlotinib

          • L01EB03 -

            Afatinib

          • L01EB04 -

            Osimertinib

          • L01EB05 -

            Rociletinib

          • L01EB06 -

            Olmutinib

          • L01EB07 -

            Dacomitinib

          • L01EB08 -

            Icotinib

        • L01EC - B-Raf serine-threonine kinase (BRAF) inhibitors
          • L01EC01 -

            Vemurafenib

          • L01EC02 -

            Dabrafenib

          • L01EC03 -

            Encorafenib

        • L01ED - Anaplastic lymphoma kinase (ALK) inhibitors
          • L01ED01 -

            Crizotinib

          • L01ED02 -

            Ceritinib

          • L01ED03 -

            Alectinib

          • L01ED04 -

            Brigatinib

          • L01ED05 -

            Lorlatinib

        • L01EE - Mitogen-activated protein kinase (MEK) inhibitors
          • L01EE01 -

            Trametinib

          • L01EE02 -

            Cobimetinib

          • L01EE03 -

            Binimetinib

          • L01EE04 -

            Selumetinib

        • L01EF - Cyclin-dependent kinase (CDK) inhibitors
          • L01EF01 -

            Palbociclib

          • L01EF02 -

            Ribociclib

          • L01EF03 -

            Abemaciclib

        • L01EG - Mammalian target of rapamycin (mTOR) kinase inhibitors
          • L01EG01 -

            Temsirolimus

          • L01EG02 -

            Everolimus

          • L01EG03 -

            Ridaforolimus

        • L01EH - Human epidermal growth factor receptor 2 (HER2) tyrosine kinase inhibitors
          • L01EH01 -

            Lapatinib

          • L01EH02 -

            Neratinib

          • L01EH03 -

            Tucatinib

        • L01EJ - Janus-associated kinase (JAK) inhibitors
          • L01EJ01 -

            Ruxolitinib

          • L01EJ02 -

            Fedratinib

          • L01EJ03 -

            Pacritinib

        • L01EK - Vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors
          • L01EK01 -

            Axitinib

          • L01EK02 -

            Cediranib

          • L01EK03 -

            Tivozanib

        • L01EL - Bruton's tyrosine kinase (BTK) inhibitors
          • L01EL01 -

            Ibrutinib

          • L01EL02 -

            Acalabrutinib

          • L01EL03 -

            Zanubrutinib

        • L01EM - Phosphatidylinositol-3-kinase (Pi3K) inhibitors
          • L01EM01 -

            Idelalisib

          • L01EM02 -

            Copanlisib

          • L01EM03 -

            Alpelisib

          • L01EM04 -

            Duvelisib

        • L01EN - Fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitors
          • L01EN01 -

            Erdafitinib

          • L01EN02 -

            Pemigatinib

          • L01EN03 -

            Infigratinib

          • L01EN04 -

            Futibatinib

        • L01EX - Other protein kinase inhibitors
          • L01EX01 -

            Sunitinib

          • L01EX02 -

            Sorafenib

          • L01EX03 -

            Pazopanib

          • L01EX04 -

            Vandetanib

          • L01EX05 -

            Regorafenib

          • L01EX06 -

            Masitinib

          • L01EX07 -

            Cabozantinib

          • L01EX08 -

            Lenvatinib

          • L01EX09 -

            Nintedanib

          • L01EX10 -

            Midostaurin

          • L01EX11 -

            Quizartinib

          • L01EX12 -

            Larotrectinib

          • L01EX13 -

            Gilteritinib

          • L01EX14 -

            Entrectinib

          • L01EX15 -

            Pexidartinib

          • L01EX17 -

            Capmatinib

          • L01EX18 -

            Avapritinib

          • L01EX19 -

            Ripretinib

          • L01EX21 -

            Tepotinib

          • L01EX22 -

            Selpercatinib

          • L01EX23 -

            Pralsetinib

      • L01F - Monoclonal Antibodies and Antibody Drug Conjugates
        • L01FA - CD20 (Clusters of Differentiation 20) inhibitors
          • L01FA01 -

            Rituximab

          • L01FA02 -

            Ofatumumab

          • L01FA03 -

            Obinutuzumab

        • L01FB - CD22 (Clusters of Differentiation 22) inhibitors
          • L01FB01 -

            Inotuzumab ozogamicin

          • L01FB02 -

            Moxetumomab pasudotox

        • L01FC - CD38 (Clusters of Differentiation 38) inhibitors
          • L01FC01 -

            Daratumumab

          • L01FC02 -

            Isatuximab

        • L01FD - HER2 (Human Epidermal Growth Factor Receptor 2) Inhibitors
          • L01FD01 -

            Trastuzumab

          • L01FD02 -

            Pertuzumab

          • L01FD03 -

            Trastuzumab emtansine

          • L01FD04 -

            Trastuzumab deruxtecan

          • L01FD05 -

            Trastuzumab duocarmazine

        • L01FE - EGFR (Epidermal Growth Factor Receptor) inhibitors
          • L01FE01 -

            Cetuximab

          • L01FE02 -

            Panitumumab

          • L01FE03 -

            Necitumumab

        • L01FF - PD-1/PDL-1 (Programmed cell death protein 1/death ligand 1) Inhibitors
          • L01FF01 -

            Nivolumab

          • L01FF02 -

            Pembrolizumab

          • L01FF03 -

            Durvalumab

          • L01FF04 -

            Avelumab

          • L01FF05 -

            Atezolizumab

          • L01FF06 -

            Cemiplimab

          • L01FF07 -

            Dostarlimab

          • L01FF08 -

            Prolgolimab

          • L01FF09 -

            Tislelizumab

          • L01FF10 -

            Retifanlimab

        • L01FG - VEGF/VEGFR (Vascular Endothelial Growth Factor) inhibitors
          • L01FG01 -

            Bevacizumab

          • L01FG02 -

            Ramucirumab

        • L01FX - Other monoclonal antibodies and antibody drug conjugates
          • L01FX01 -

            Edrecolomab

          • L01FX02 -

            Gemtuzumab ozogamicin

          • L01FX03 -

            Catumaxomab

          • L01FX04 -

            Ipilimumab

          • L01FX05 -

            Brentuximab vedotin

          • L01FX06 -

            Dinutuximab beta

          • L01FX07 -

            Blinatumomab

          • L01FX08 -

            Elotuzumab

          • L01FX09 -

            Mogamulizumab

          • L01FX10 -

            Olaratumab

          • L01FX11 -

            Bermekimab

          • L01FX12 -

            Tafasitamab

          • L01FX13 -

            Enfortumab vedotin

          • L01FX14 -

            Polatuzumab vedotin

          • L01FX15 -

            Belantamab mafodotin

          • L01FX16 -

            Oportuzumab monatox

          • L01FX17 -

            Sacituzumab govitecan

          • L01FX18 -

            Amivantamab

      • L01X - Other antineoplastic agents
        • L01XA - Platinum compounds
          • L01XA01 -

            Cisplatin

          • L01XA02 -

            Carboplatin

          • L01XA03 -

            Oxaliplatin

          • L01XA04 -

            Satraplatin

          • L01XA05 -

            Polyplatillen

        • L01XB - Methylhydrazines
          • L01XB01 -

            Procarbazine

        • L01XC - Monoclonal antibodies
          • L01XC02 -

            Rituximab

          • L01XC03 -

            Trastuzumab

          • L01XC04 -

            Alemtuzumab

          • L01XC05 -

            Gemtuzumab

          • L01XC06 -

            Cetuximab

          • L01XC07 -

            Bevacizumab

          • L01XC08 -

            Panitumumab

          • L01XC09 -

            Catumaxomab

          • L01XC10 -

            Ofatumumab

          • L01XC11 -

            Ipilimumab

        • L01XD - Sensitizers used in photodynamic/radiation therapy
          • L01XD01 -

            Porfimer sodium

          • L01XD03 -

            Methyl aminolevulinate

          • L01XD04 -

            Aminolevulinic acid

          • L01XD05 -

            Temoporfin

          • L01XD06 -

            Efaproxiral

          • L01XD07 -

            Padeliporfin

        • L01XE - Protein kinase inhibitors
          • L01XE01 -

            Imatinib

          • L01XE02 -

            Gefitinib

          • L01XE03 -

            Erlotinib

          • L01XE04 -

            Sunitinib

          • L01XE05 -

            Sorafenib

          • L01XE06 -

            Dasatinib

          • L01XE07 -

            Lapatinib

          • L01XE08 -

            Nilotinib

          • L01XE09 -

            Temsirolimus

          • L01XE10 -

            Everolimus

          • L01XE11 -

            Pazopanib

        • L01XF - Retinoids for cancer treatment
          • L01XF01 -

            Tretinoin

          • L01XF02 -

            Alitretinoin

          • L01XF03 -

            Bexarotene

        • L01XG - Proteasome inhibitors
          • L01XG01 -

            Bortezomib

          • L01XG02 -

            Carfilzomib

          • L01XG03 -

            Ixazomib

        • L01XH - Histone deacetylase (HDAC) inhibitors
          • L01XH01 -

            Vorinostat

          • L01XH02 -

            Romidepsin

          • L01XH03 -

            Panobinostat

          • L01XH04 -

            Belinostat

          • L01XH05 -

            Entinostat

        • L01XJ - Hedgehog pathway inhibitors
          • L01XJ01 -

            Vismodegib

          • L01XJ02 -

            Sonidegib

          • L01XJ03 -

            Glasdegib

        • L01XK - Poly (ADP-ribose) Polymerase (PARP) Inhibitors
          • L01XK01 -

            Olaparib

          • L01XK02 -

            Niraparib

          • L01XK03 -

            Rucaparib

          • L01XK04 -

            Talazoparib

          • L01XK05 -

            Veliparib

          • L01XK06 -

            Pamiparib

        • L01XX - Other antineoplastic agents
          • L01XX01 -

            Amsacrine

          • L01XX02 -

            Asparaginase

          • L01XX03 -

            Altretamine

          • L01XX05 -

            Hydroxycarbamide

          • L01XX07 -

            Lonidamine

          • L01XX08 -

            Pentostatin

          • L01XX10 -

            Masoprocol

          • L01XX11 -

            Estramustine

          • L01XX16 -

            Mitoguazone

          • L01XX17 -

            Topotecan

          • L01XX18 -

            Tiazofurine

          • L01XX19 -

            Irinotecan

          • L01XX23 -

            Mitotane

          • L01XX24 -

            Pegaspargase

          • L01XX25 -

            Bexarotene

          • L01XX27 -

            Arsenic trioxide

          • L01XX29 -

            Denileukin diftitox

          • L01XX32 -

            Bortezomib

          • L01XX33 -

            Celecoxib

          • L01XX35 -

            Anagrelide

          • L01XX36 -

            Oblimersen

          • L01XX37 -

            Sitimagene ceradenovec

          • L01XX40 -

            Omacetaxine mepesuccinate

          • L01XX41 -

            Eribulin

          • L01XX44 -

            Aflibercept

          • L01XX51 -

            Talimogene laherparepvec

          • L01XX52 -

            Venetoclax

          • L01XX53 -

            Vosaroxin

          • L01XX57 -

            Plitidepsin

          • L01XX58 -

            Epacadostat

          • L01XX59 -

            Enasidenib

          • L01XX62 -

            Ivosidenib

          • L01XX66 -

            Selinexor

          • L01XX67 -

            Tagraxofusp

          • L01XX69 -

            Lurbinectedin

          • L01XX70 -

            Axicabtagene ciloleucel

          • L01XX71 -

            Tisagenlecleucel

          • L01XX72 -

            Tazemetostat

          • L01XX73 -

            Sotorasib

          • L01XX74 -

            Belzutifan

        • L01XY - Combinations of antineoplastic agents
          • L01XY01 -

            Cytarabine and daunorubicin

          • L01XY02 -

            Pertuzumab and trastuzumab

    • L02 - Endocrine therapy
      • L02A - Hormones and related agents
        • L02AA - Estrogens
          • L02AA01 -

            Diethylstilbestrol

          • L02AA02 -

            Polyestradiol phosphate

          • L02AA03 -

            Ethinylestradiol

          • L02AA04 -

            Fosfestrol

        • L02AB - Progestogens
          • L02AB01 -

            Megestrol

          • L02AB02 -

            Medroxyprogesterone

          • L02AB03 -

            Gestonorone

        • L02AE - Gonadotrophin releasing hormone analogues
          • L02AE01 -

            Buserelin

          • L02AE02 -

            Leuprorelin

          • L02AE03 -

            Goserelin

          • L02AE04 -

            Triptorelin

          • L02AE05 -

            Histrelin

          • L02AE51 -

            Leuprorelin and bicalutamide

      • L02B - Hormone antagonists and related agents
        • L02BA - Anti-estrogens
          • L02BA01 -

            Tamoxifen

          • L02BA02 -

            Toremifene

          • L02BA03 -

            Fulvestrant

        • L02BB - Anti-androgens
          • L02BB01 -

            Flutamide

          • L02BB02 -

            Nilutamide

          • L02BB03 -

            Bicalutamide

          • L02BB04 -

            Enzalutamide

          • L02BB05 -

            Apalutamide

          • L02BB06 -

            Darolutamide

        • L02BG - Aromatase inhibitors
          • L02BG01 -

            Aminoglutethimide

          • L02BG02 -

            Formestane

          • L02BG03 -

            Anastrozole

          • L02BG04 -

            Letrozole

          • L02BG05 -

            Vorozole

          • L02BG06 -

            Exemestane

        • L02BX - Other hormone antagonists and related agents
          • L02BX01 -

            Abarelix

          • L02BX02 -

            Degarelix

          • L02BX03 -

            Abiraterone

          • L02BX04 -

            Relugolix

    • L03 - Immunostimulants
      • L03A - Immunostimulants
        • L03AA - Colony stimulating factors
          • L03AA02 -

            Filgrastim

          • L03AA03 -

            Molgramostim

          • L03AA09 -

            Sargramostim

          • L03AA10 -

            Lenograstim

          • L03AA12 -

            Ancestim

          • L03AA13 -

            Pegfilgrastim

          • L03AA14 -

            Lipegfilgrastim

          • L03AA15 -

            Balugrastim

          • L03AA16 -

            Empegfilgrastim

          • L03AA17 -

            Pegteograstim

        • L03AB - Interferons
          • L03AB01 -

            Interferon alfa natural

          • L03AB02 -

            Interferon beta natural

          • L03AB03 -

            Interferon gamma

          • L03AB04 -

            Interferon alfa-2a

          • L03AB05 -

            Interferon alfa-2b

          • L03AB06 -

            Interferon alfa-n1

          • L03AB07 -

            Interferon beta-1a

          • L03AB08 -

            Interferon beta-1b

          • L03AB09 -

            Interferon alfacon-1

          • L03AB10 -

            Peginterferon alfa-2b

          • L03AB11 -

            Peginterferon alfa-2a

          • L03AB12 -

            Albinterferon alfa-2b

          • L03AB13 -

            Peginterferon beta-1a

          • L03AB14 -

            Cepeginterferon alfa-2b

          • L03AB15 -

            Ropeginterferon alfa-2b

          • L03AB16 -

            Peginterferon alfacon-2

          • L03AB60 -

            Peginterferon alfa-2b, combinations

          • L03AB61 -

            Peginterferon alfa-2a, combinations

        • L03AC - Interleukins
          • L03AC01 -

            Aldesleukin

          • L03AC02 -

            Oprelvekin

        • L03AX - Other immunostimulants
          • L03AX01 -

            Lentinan

          • L03AX02 -

            Roquinimex

          • L03AX03 -

            Bcg vaccine

          • L03AX04 -

            Pegademase

          • L03AX05 -

            Pidotimod

          • L03AX07 -

            Poly i:c

          • L03AX08 -

            Poly iclc

          • L03AX09 -

            Thymopentin

          • L03AX10 -

            Immunocyanin

          • L03AX11 -

            Tasonermin

          • L03AX12 -

            Melanoma vaccine

          • L03AX13 -

            Glatiramer acetate

          • L03AX14 -

            Histamine dihydrochloride

          • L03AX15 -

            Mifamurtide

          • L03AX16 -

            Plerixafor

          • L03AX17 -

            Sipuleucel-t

          • L03AX18 -

            Cridanimod

          • L03AX19 -

            Dasiprotimut-t

          • L03AX21 -

            Elapegademase

    • L04 - Immunosuppressants
      • L04A - Immunosuppressants
        • L04AA - Selective immunosuppressants
          • L04AA02 -

            Muromonab-cd3

          • L04AA03 -

            Antilymphocyte immunoglobulin (horse)

          • L04AA04 -

            Antithymocyte immunoglobulin

          • L04AA06 -

            Mycophenolic acid

          • L04AA10 -

            Sirolimus

          • L04AA13 -

            Leflunomide

          • L04AA15 -

            Alefacept

          • L04AA18 -

            Everolimus

          • L04AA19 -

            Gusperimus

          • L04AA21 -

            Efalizumab

          • L04AA22 -

            Abetimus

          • L04AA23 -

            Natalizumab

          • L04AA24 -

            Abatacept

          • L04AA25 -

            Eculizumab

          • L04AA26 -

            Belimumab

          • L04AA27 -

            Fingolimod

          • L04AA28 -

            Belatacept

          • L04AA29 -

            Tofacitinib

          • L04AA31 -

            Teriflunomide

          • L04AA32 -

            Apremilast

          • L04AA33 -

            Vedolizumab

          • L04AA34 -

            Alemtuzumab

          • L04AA35 -

            Begelomab

          • L04AA36 -

            Ocrelizumab

          • L04AA37 -

            Baricitinib

          • L04AA38 -

            Ozanimod

          • L04AA39 -

            Emapalumab

          • L04AA40 -

            Cladribine

          • L04AA41 -

            Imlifidase

          • L04AA42 -

            Siponimod

          • L04AA43 -

            Ravulizumab

          • L04AA44 -

            Upadacitinib

          • L04AA45 -

            Filgotinib

          • L04AA46 -

            Itacitinib

          • L04AA47 -

            Inebilizumab

          • L04AA48 -

            Belumosudil

          • L04AA49 -

            Peficitinib

          • L04AA50 -

            Ponesimod

          • L04AA51 -

            Anifrolumab

          • L04AA52 -

            Ofatumumab

          • L04AA53 -

            Teprotumumab

          • L04AA54 -

            Pegcetacoplan

          • L04AA55 -

            Sutimlimab

          • L04AA56 -

            Deucravacitinib

        • L04AB - Tumor necrosis factor alpha (tnf-alpha) inhibitors
          • L04AB01 -

            Etanercept

          • L04AB02 -

            Infliximab

          • L04AB03 -

            Afelimomab

          • L04AB04 -

            Adalimumab

          • L04AB05 -

            Certolizumab pegol

          • L04AB06 -

            Golimumab

          • L04AB07 -

            Opinercept

        • L04AC - Interleukin inhibitors
          • L04AC01 -

            Daclizumab

          • L04AC02 -

            Basiliximab

          • L04AC03 -

            Anakinra

          • L04AC04 -

            Rilonacept

          • L04AC05 -

            Ustekinumab

          • L04AC07 -

            Tocilizumab

          • L04AC08 -

            Canakinumab

          • L04AC09 -

            Briakinumab

          • L04AC10 -

            Secukinumab

          • L04AC11 -

            Siltuximab

          • L04AC12 -

            Brodalumab

          • L04AC13 -

            Ixekizumab

          • L04AC14 -

            Sarilumab

          • L04AC15 -

            Sirukumab

          • L04AC16 -

            Guselkumab

          • L04AC17 -

            Tildrakizumab

          • L04AC18 -

            Risankizumab

          • L04AC19 -

            Satralizumab

          • L04AC20 -

            Netakimab

          • L04AC21 -

            Bimekizumab

          • L04AC22 -

            Spesolimab

        • L04AD - Calcineurin inhibitors
          • L04AD01 -

            Ciclosporin

          • L04AD02 -

            Tacrolimus

          • L04AD03 -

            Voclosporin

        • L04AE - Sphingosine 1-phosphate (S1P) receptor modulators
        • L04AF - Janus-associated kinase (JAK) inhibitors
        • L04AG - Monoclonal antibodies
        • L04AH - Mammalian target of rapamycin (mTOR) kinase inhibitors
        • L04AJ - Complement inhibitors
        • L04AK - Dihydroorotate dehydrogenase (DHODH) inhibitors
        • L04AX - Other immunosuppressants
          • L04AX01 -

            Azathioprine

          • L04AX02 -

            Thalidomide

          • L04AX03 -

            Methotrexate

          • L04AX04 -

            Lenalidomide

          • L04AX05 -

            Pirfenidone

          • L04AX06 -

            Pomalidomide

          • L04AX07 -

            Dimethyl fumarate

          • L04AX08 -

            Darvadstrocel

          • L04AX09 -

            Diroximel fumarate

  • Network visualization
  • Network statistics
  • Network analysis and comparison
  • Network pharmacogenomics
  • Network adverse drug reaction

Read More

  • Target
  • Enzyme
  • Transporter
  • Carrier

Mode of action

  • Small Molecule
  • Biotech

Drug type

  • Nutraceutical
  • Experimental
  • Investigational
  • Approved
  • VetApproved
  • Illicit

Drug clinical status

  • Phase 1
  • Phase 2
  • Phase 3
  • Phase 4

Clinical trial phases of Drug-disease association studies

Disease class count

Read More

Read More

There is no pharmacogenomics data associated with drugs and genes (proteins) in this ATC code!

Clinical PGx data (Variant drug response data)
Burden data

Please kindly wait when the data is being loaded!

Read More

Target         No. of drugs                 List of drugs                                        PGx information                               Other                

Mode of Action

Drug type

Drug clinical status